Odyssey Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
TPG entities reported significant changes in beneficial ownership of Odyssey Therapeutics common stock following the company's initial public offering.
NASDAQ
Dimension Capital II, L.P. reported the conversion of preferred stock and a new purchase of common stock in Odyssey Therapeutics, Inc.
NASDAQ
SR One Capital Management reports the conversion of preferred stock and warrant exercises in connection with the Odyssey Therapeutics IPO.
NASDAQ
Director Jeffrey M. Leiden acquired 5,000 shares of Odyssey Therapeutics, Inc. and converted various preferred holdings into common stock.
NASDAQ
Chief Financial Officer Jason Haas acquired 1,000 shares of Odyssey Therapeutics, Inc. common stock at $20 per share.
NASDAQ
Director Li Nan disclosed the conversion of preferred stock and participation in the Odyssey Therapeutics IPO.
NASDAQ
Director Ian F. Smith was granted 27,393 stock options in Odyssey Therapeutics, Inc. as part of a standard equity compensation arrangement.
NASDAQ
Director Valerie Odegard was granted 27,393 stock options in Odyssey Therapeutics, Inc. with an exercise price of $18.00.
NASDAQ
Director Shelley Chu acquired 11,111 shares of Odyssey Therapeutics, Inc. (ODTX) at $18 per share in the company's IPO.
NASDAQ
Director Ourania Tatsis was granted 27,393 stock options in Odyssey Therapeutics, Inc. vesting in one year.
NASDAQ
Natalie Dales, Chief of Research Operations and Portfolio Strategy at Odyssey Therapeutics, was granted 79,773 stock options.
NASDAQ
Director Timothy P. Walbert was granted 27,393 stock options in Odyssey Therapeutics, Inc. with an exercise price of $18.00.
NASDAQ
CEO Gary D. Glick reports the conversion of preferred stock into common shares and the receipt of a new stock option grant.
NASDAQ
Interim CMO Anthony W. Opipari converted preferred stock and exercised warrants in conjunction with the company's IPO.
NASDAQ
Senior Vice President of Strategy and Business Development, Collin M. Todd, was granted 93,904 stock options in Odyssey Therapeutics.